An Innovator in Immunoresolution Pharmacology

Thetis is a biopharmaceutical company focused on developing novel immunoresolvent agents targeting diseases with underlying inflammation. These agents deliver specialized proresolving mediators (SPMs) that rescue failed inflammation and promote return to homeostasis by downregulating proinflammatory cytokines, clearing out cell debris, and restoring tissue and vascular integrity.

Using our HEALER™ platform technology, we create novel small molecule derivatives of the natural SPMs and their Omega-3 precursor fatty acids. This enables efficient development of therapeutic agents with composition of matter patent protection, enhanced bioavailability and stability, a broad range of dosage forms, and low risk of off-target effects.

Learn more about our HEALER platform. »»